Get started
Author

Lada Mitchell

Observed names: L Mitchell, L. Mitchell, Mitchell, Lada
Observed institutions: F. Hoffmann-La Roche AG, Universidad Complutense de Madrid, Novartis (Switzerland), University of Udine, Universitat de València, Aix-Marseille Université, Hadassah Medical Center, University Hospital Heidelberg, Hospital General Universitario Gregorio Marañón, Centre Hospitalier Universitaire de Lille, Sorbonne Université, Assistance Publique Hôpitaux de Marseille, Hospital Son Llatzer, Johnson & Johnson (Switzerland), Russian Cancer Research Center NN Blokhin, Hospital Clínico Universitario de Valencia, Hospital Universitario 12 De Octubre, Centre Léon Bérard, Roche (France), Mount Vernon Cancer Centre, National Center for Tumor Diseases, Institute of Oncology NN Petrov, Mount Vernon Hospital, Moscow City Oncology Hospital №62, Instituto Nazionale Tumori Regina Elena, Actelion (Switzerland)
OpenAlex ID: A5107898117
Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial
2004 · Stevo Julius, Sverre E Kjeldsen, et al. · The Lancet · 2,555
Applied Multivariate Statistics for the Social Sciences
2003 · Lada Mitchell · Journal of the Royal Statistical Society Series D (The Statistician) · 986
Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial
2004 · Michael A Weber, Stevo Julius, et al. · The Lancet · 591
Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non–Small-Cell Lung Cancer: AVAPERL (MO22089)
2013 · Fabrice Barlesi, Arnaud Scherpereel, et al. · Journal of Clinical Oncology · 323
Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an open-label pilot study
2013 · Reinhard Dummer, Simone M. Goldinger, et al. · European Journal of Cancer · 289
Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study
2014 · James Larkin, Michele Del Vecchio, et al. · The Lancet Oncology · 278
Generalized, Linear, and Mixed Models
2003 · Lada Mitchell · Journal of the Royal Statistical Society Series D (The Statistician) · 276
Efficacy and Safety of Bevacizumab in Metastatic Colorectal Cancer: Pooled Analysis From Seven Randomized Controlled Trials
2013 · Herbert I. Hurwitz, Niall C. Tebbutt, et al. · The Oncologist · 237
PDF
Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial
2015 · Andres M. Poveda, Frédéric Selle, et al. · Journal of Clinical Oncology · 231
PDF
An open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with brain metastases.
2011 · R. Dummer, J. Rinderknecht, et al. · Journal of Clinical Oncology · 62
Phase II Study of Bevacizumab in Combination with Trastuzumab and Capecitabine as First-Line Treatment for HER-2-positive Locally Recurrent or Metastatic Breast Cancer
2012 · Miguel Martín, Anatoly Makhson, et al. · The Oncologist · 52
LocoMMotion: a study of real-life current standards of care in triple-class exposed patients with relapsed/refractory multiple myeloma – 2-year follow-up (final analysis)
2024 · María-Victoria Mateos, Katja Weisel, et al. · Leukemia · 37
PDF
VE-BASKET, a Simon 2-stage adaptive design, phase II, histology-independent study in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m): Activity of vemurafenib (VEM) with or without cetuximab (CTX) in colorectal cancer (CRC).
2014 · Josep Tabernero, Emily Chan, et al. · Journal of Clinical Oncology · 32
VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).
2014 · David Michael Hyman, Jean-Yves Blay, et al. · Journal of Clinical Oncology · 21
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension
2022 · J. Gerry Coghlan, Sean Gaine, et al. · ERJ Open Research · 20
PDF
A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: An open-label, two-cohort, phase II study (VELVET).
2012 · Edith A. Perez, Jose Manuel Lopez-Vega, et al. · Journal of Clinical Oncology · 18
Open-Label Pilot Study of Vemurafenib in Previously Treated Metastatic Melanoma (MM) Patients (PTS) with Symptomatic Brain Metastases (BM)
2012 · R. Dummer, S. Goldinger, et al. · Annals of Oncology · 14
An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
2012 · James M. G. Larkin, Paola Queirolo, et al. · Journal of Clinical Oncology · 14
Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset
2024 · Richard Channick, Kelly M. Chin, et al. · Cardiology and Therapy · 13
PDF
A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS)
2016 · Egbert F. Smit, Yi-Long Wu, et al. · Lung Cancer · 13
Vismodegib, a Hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study interim analysis in 300 patients.
2013 · Jean Jacques Grob, Rainer Kunstfeld, et al. · Journal of Clinical Oncology · 13
Abstract OT1-1-02: A single-arm phase IIIb study of pertuzumab and trastuzumab with a taxane as first-line therapy for patients with HER2-positive advanced breast cancer (PERUSE)
2012 · T Bachelot, E Ciruelos, et al. · Cancer Research · 12
Pertuzumab in combination with trastuzumab plus an aromatase inhibitor in patients with hormone receptor-positive, HER2-positive metastatic breast cancer: A randomized phase II study (PERTAIN).
2012 · Mothaffar F. Rimawi, Christopher John Poole, et al. · Journal of Clinical Oncology · 9
Efficacy and safety of chemotherapy (CT) ± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.
2015 · Christian Kurzeder, Isabel Bover, et al. · Journal of Clinical Oncology · 6
MIKIE: A randomized, double-blind, regimen-controlled, phase II, multicenter study to assess the efficacy and safety of two different vismodegib regimens in patients with multiple basal cell carcinomas.
2014 · Rainer Kunstfeld, Axel Hauschild, et al. · Journal of Clinical Oncology · 6
Works count: 55
Citation count: 6,127
H-index: 16
I10-index: 22
Year
Topic
Type